2004

Go to navigation
Go to content

Pages
1
2
Next

- 08 December 2004
- AstraZeneca Donated Two Hundred Thousand Yuan To Support Charity Community Program in Wuxi
- 29 November 2004
- NEXIUM RECEIVES FDA APPROVAL FOR RISK REDUCTION OF NSAID-ASSOCIATED STOMACH ULCERS
- 22 November 2004
- ASTRAZENECA AND CAMBRIDGE ANTIBODY TECHNOLOGY ANNOUNCE MAJOR STRATEGIC ALLIANCE TO DISCOVER AND DEVELOP HUMAN ANTIBODY THERAPEUTICS IN INFLAMMATORY DISORDERS
- 21 October 2004
- THIRD QUARTER AND AND NINE MONTHS RESULTS 2004
- 26 September 2004
- A Decade of Cooperation, A Decade of Innovation AstraZeneca and Sinopharm Group Celebrate 10 Years of Cooperation
- 16 September 2004
- New Indications for NEXIUM® in Healing and Prevention of Nsaid-Associated Ulcers
- 08 September 2004
- CRESTOR™ (ROSUVASTATIN) REACHES 10 MILLION PRESCRIPTION MILESTONE
- 08 September 2004
- CRESTOR™ TAKES LEAD IN INTERNATIONAL STUDY OF STATIN TREATMENT FOR PATIENTS WITH THE METABOLIC SYNDROME
- 07 September 2004
- RHINOCORT® AQUA™ RECEIVES PREGNANCY CATEGORY B LABEL IN US
- 23 August 2004
- AstraZeneca Celebrates 10 Years in Guangzhou AstraZeneca moves into new offices and reconfirms its commitment to southern China

Pages
1
2
Next

Quick links

Page tools

中文版

www.astrazeneca.com.cn

Information contained in this site is solely intended for the use of residents of mainland China.